NRG-GY018 Trial to Rule Benefit of IO/Chemo in Advanced Endometrial Cancer

Commentary
Video

The phase 3 NRG GY018 trial added immunotherapy to chemotherapy in patients with recurrent endometrial cancer, regardless of mismatch repair deficient or proficient disease status, according to Ramez N. Eskander, MD.

The phase 3 NRG-GY018 trial (NCT03914612) aimed to test the benefit of adding pembrolizumab (Keytruda) with carboplatin and paclitaxel in patients with stage III or IVA, stage IVB, or recurrent endometrial cancer, according to Ramez N. Eskander, MD.

In a conversation with CancerNetwork®, Eskander, a gynecologic oncologist and assistant professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Diego Health, discussed the assessment of this treatment in patients with both mismatch repair deficient (dMMR) disease and mismatch repair proficient (pMMR) disease.

Transcript:

NRG GY018 was designed as a phase 3, double-blind clinical trial examining the therapeutic benefit of adding pembrolizumab to standard-of-care carboplatin and paclitaxel and then continued as maintenance vs placebo plus carboplatin and paclitaxel with placebo maintenance. Maintenance was for up to 2 years. The trial was designed specifically to adjudicate the benefit of adding immunotherapy in patients with advanced stage or recurrent disease in 2 separate patient populations: the dMMR, or mismatch repair deficient population, and the pMMR, or mismatch repair proficient population. The reason that we intentionally looked at these patient cohorts separately is because we know that, biologically, there was a strong rationale for the benefit of immunotherapy in the dMMR [population].

We wanted to independently assess the benefit in the pMMR population. The hypothesis was that, if you give cytotoxic chemotherapy, as we’ve seen in other solid tumors like lung cancer, you may be able to augment the response to immunotherapy in a disease that doesn’t respond well to immunotherapy alone: pMMR endometrial cancer. That’s because cytotoxic chemotherapy can be immunogenic on its own. It can increase neoantigen presentation. It can reduce myeloid-derived suppressor cells or regulatory T-cell activity. There are multiple hypotheses about why combining these would be beneficial. The trial was conducted to help us determine whether or not there would be a therapeutic benefit to adding immunotherapy to chemotherapy in both of these patient cohorts.

Reference

Eskander RN, Sill MW, Beffa L, et al. SEMINAL: Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: the phase 3, NRG GY018 study. 2023 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS). November 5-7, 2023; Seoul, South Korea.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Related Content